Companies join forces to advance predictive and prescriptive recommendations for people with diabetes INDIANAPOLIS and MOUNTAIN VIEW, Calif., Jan. 8, 2018 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Livongo Health, a leading consumer digital health company focused on empowering all people with chronic conditions to live better and healthier lives, today announced a strategic collaboration to study real-world evidence and […]
Company supports Diabetes Scholars Foundation Scholarship fund for fourth year in a row ROLLING MEADOWS, Ill. and INDIANAPOLIS, Feb. 11, 2016 /PRNewswire/ — Attending college is a major milestone for many young people, but for those with type 1 diabetes, the journey can be extra demanding. Not only do these students juggle class schedules, assignments […]
Lilly Diabetes commits $93,000 to support Association “Camperships” INDIANAPOLIS and ALEXANDRIA, Va., Feb. 3, 2016 /PRNewswire/ — A three-year survey by the American Diabetes Association (Association) shows attending summer camp can do much more than lift the spirits of children with type 1 diabetes. Surveys conducted with caregivers before and after their child attended an […]
INDIANAPOLIS, Jan. 27, 2016 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced an arrangement to partner with Roche Diagnostics on its ongoing development of a commercially scalable cerebrospinal fluid assay for amyloid-beta 1-42. Together with tau tangles, the presence of amyloid in the brain is a key marker of Alzheimer’s disease, a condition […]
– BASAGLAR is the first FDA-approved follow-on insulin glargine treatment – BASAGLAR will be available in the U.S. starting on December 15, 2016 INDIANAPOLIS and RIDGEFIELD, Conn., Dec. 16, 2015 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced that the U.S. Food and Drug Administration (FDA) granted […]
New Drug Application follows submission of Marketing Authorisation Application to the European Medicines Agency INDIANAPOLIS and RIDGEFIELD, Conn., Dec. 20, 2013 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of the New Drug Application (NDA) for LY2963016, an […]
New resources housed on T1EverydayMagic.com combine the expertise of Lilly Diabetes with the magic of Disney INDIANAPOLIS, Dec. 19, 2013 /PRNewswire/ — Lilly Diabetes and Disney today announced that their custom books for children and families with type 1 diabetes are now available online. The digital books explore real-life challenges and stories of children with […]
INDIANAPOLIS, Dec. 5, 2013 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today that results from three studies of edivoxetine did not meet the primary study objective of superior efficacy in depression after eight weeks of treatment. When added to a selective serotonin reuptake inhibitor (SSRI), edivoxetine did not separate from placebo on the […]
More than 10,000 people with self-reported and diagnosed type 2 diabetes and more than 6,500 treating-physicians from 26 countries to take part in new survey RIDGEFIELD, Conn. and INDIANAPOLIS, Dec. 2, 2013 /PRNewswire/ — Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced the launch of the largest multinational survey to investigate early […]
New sponsorship of “Red Riders®”–cyclists with diabetes–added in 5 cities INDIANAPOLIS, Nov. 19, 2013 /PRNewswire/ — News Highlights: For a 2nd year, #Lilly #Diabetes supports the American Diabetes Association’s Tour de Cure cycling event to help #StopDiabetes New in 2014, #Lilly #Diabetes to support #RedRider cyclists with #diabetes in 5 cities Lilly Tour de Cure […]